1. Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.
- Author
-
Diaz Martinez JP, Aubry de Maraumont T, Natty Sánchez E, Camacho Cordero LM, and Yeh E
- Subjects
- Humans, Female, Mexico epidemiology, Aged, Teriparatide therapeutic use, Teriparatide economics, Markov Chains, Osteoporotic Fractures prevention & control, Osteoporotic Fractures economics, Osteoporotic Fractures epidemiology, Quality-Adjusted Life Years, Bone Density drug effects, Aged, 80 and over, Middle Aged, Fractures, Bone epidemiology, Fractures, Bone prevention & control, Cost-Effectiveness Analysis, Cost-Benefit Analysis, Osteoporosis, Postmenopausal drug therapy, Osteoporosis, Postmenopausal economics, Denosumab therapeutic use, Denosumab economics, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal economics, Bone Density Conservation Agents therapeutic use, Bone Density Conservation Agents economics
- Abstract
Introduction: This study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk of fractures in Mexican women., Methods: A Markov model was used to assess the relative cost effectiveness of 1 year of romosozumab versus 2 years of teriparatide, both sequenced to denosumab for a total treatment duration of 5 years. Outcomes for a cohort of women with a mean age of 74 years, a T-score ≤-2.5 and a previous fragility fracture were simulated over a lifetime horizon. The analysis was conducted from the perspective of the Mexican healthcare system and used a discount rate of 5% per annum. To inform relative fracture incidence, the bone mineral density (BMD) advantage of romosozumab over teriparatide was translated into relative risks of fracture, using relationships provided by a meta-regression of osteoporosis therapy trials. Outcomes were assessed in terms of lifetime costs (2023 Mexican pesos), quality-adjusted life years (QALYs) and life-years gained (LYs)., Results: Base case results showed that, compared with teriparatide/ denosumab, romosozumab/ denosumab reduced costs by $51,363 MXN per patient and yielded 0.03 additional QALYs and 0.01 LYs. Scenario analyses and probabilistic sensitivity analyses confirmed that results are robust to uncertainty in model assumptions and inputs., Conclusions: Results show that romosozumab/ denosumab produces greater health benefits at a lower total cost than teriparatide/ denosumab., Competing Interests: TAM, LG, EY and LMC are employed by Amgen. JPDM has served as a consultant for Amgen and has received research grants from them. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2025 Diaz Martinez et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2025
- Full Text
- View/download PDF